Ibio, INC 8-K filings

iBio, Inc. announced the appointment of Dr. Molly Carr as its new Chief Medical Officer, a move aimed at bolstering its clinical strategy and advancing its pipeline.

iBio, Inc. announced its 2026 Annual Meeting of Stockholders will be held on October 14, 2026, and has updated deadlines for shareholder proposals and director nominations.

iBio, Inc. announced new preclinical data for its Activin E antibody candidate, IBIO-610, showing significant reduction in active Activin E levels and potential for fat-selective weight loss.

iBio, Inc. has appointed Dr. Elizabeth Stoner to its Board of Directors as the company prepares to enter its first human clinical trials.

iBio, Inc. clarifies the expiration date for its Series G Warrants following regulatory progress for its IBIO-600 clinical trial.

iBio, Inc. announced it has received regulatory clearance in Australia to begin its first-in-human clinical trial for IBIO-600, a novel antibody targeting muscle loss.

iBio, Inc. entered into a new $100 million at-the-market equity offering program with Jefferies LLC, simultaneously terminating its previous ATM agreement.

iBio, Inc. reported Q2 FY26 financial results, securing $26 million in PIPE financing and advancing key preclinical programs towards clinical trials.

iBio, Inc. announced a $26 million private placement with institutional investors to fund its preclinical cardiometabolic programs and extend its cash runway into 2028.

iBio, Inc. stockholders approved the election of two Class II directors, ratified Grassi & Co. as independent auditors, and endorsed executive compensation at their Annual Meeting.

iBio, Inc. filed an 8-K to announce the update of its corporate presentation for use in meetings with investors and analysts.

iBio reports Q1 FY2026 financial results, highlighting a strengthened cash position and promising preclinical data for its Activin E antibody, IBIO-610, for obesity treatment.

iBio, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a previously reported non-compliance issue.

iBio, Inc. announced new preclinical data for its Activin E antibody candidate, IBIO-610, projecting a human half-life of up to 100 days, potentially enabling twice-yearly dosing for fat-selective weight loss.

iBio, Inc. announced its fiscal year 2025 financial results, highlighting significant preclinical pipeline advancements in cardiometabolic diseases and obesity, alongside successful capital raises and corporate governance enhancements.

iBio, Inc. announced the pricing of an underwritten public offering of pre-funded warrants and Series G and H warrants, aiming to raise approximately $50 million initially, with potential for an additional $50 million.

iBio, Inc. announced preliminary unaudited cash of $8.8 million as of June 30, 2025, alongside an updated corporate presentation detailing its AI-driven preclinical pipeline for obesity and cardiometabolic diseases.

iBio, Inc. has received a notice from Nasdaq regarding its failure to maintain the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

iBio, Inc. has updated its corporate presentation, showcasing a pipeline of breakthrough antibody therapies for obesity and cardiometabolic diseases, with key development milestones contingent on securing financing.

iBio, Inc. announced an agreement with Safi Biotherapeutics Inc. to extend the maturity date of a $1.5 million promissory note from June 19, 2025, to June 19, 2026, contingent on the payment of all accrued interest.

iBio, Inc. announced its fiscal third quarter 2025 financial results, highlighting progress in its pipeline and a recent $6.2 million warrant inducement equity raise.

iBio, Inc. has entered into an exclusive licensing agreement with AstralBio, Inc. for a preclinical first-in-class antibody targeting Activin E to develop precision antibody therapies for cardiometabolic diseases and obesity.

iBio, Inc. releases an updated corporate presentation showcasing advancements in its AI-driven antibody discovery platform, particularly in obesity and cardiometabolic disease programs, including promising preclinical data for IBIO-600 and an Activin E antibody.

iBio reports positive non-human primate data for IBIO-600, showing extended half-life and muscle growth, and preclinical data for a first-in-class Activin E antibody demonstrating fat-selective weight loss.

iBio, Inc. announces its common stock has been approved for listing on the Nasdaq Capital Market and will transfer its stock exchange listing from the NYSE American.

iBio, Inc. announces its fiscal second quarter 2025 financial results, reporting revenue of $0.2 million and a net loss of $4.4 million, while also highlighting advancements in its preclinical pipeline and board appointments.

iBio, Inc. announced the closing of a private placement offering with its Board of Directors and Officers, raising approximately $655,000 for working capital.

iBio, Inc. has updated its corporate presentation, highlighting its AI-driven antibody discovery platform and advancements in developing treatments for obesity and cardiometabolic disorders.

iBio has entered into an exclusive license agreement with AstralBio for a novel anti-myostatin antibody, named IBIO-600, and is developing a bispecific antibody targeting myostatin/activin A to treat obesity and cardiometabolic disorders.

iBio, Inc. has announced the appointment of David Arkowitz and Antnio Parada as new independent directors, bringing significant financial and antibody discovery expertise to the board.